73756-39-5

Basic information

• Product Name: 2-tetradecyloctadecanoic acid
• Synonyms: 2-tetradecyloctadecanoic acid;Octadecanoic acid, 2-tetradecyl-
• CAS NO: 73756-39-5
• Molecular Formula: C₃₂H₆₄O₂
• Molecular Weight: 480.84936
• EINECS: 277-586-1
• Mol File: 73756-39-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 580.1°C at 760 mmHg
• Flash Point: 329.1°C
• Appearance: /
• Density: 0.871g/cm³
• Vapor Pressure: 5.77E-15mmHg at 25°C
• Refractive Index: 1.462
• CAS DataBase Reference: 2-tetradecyloctadecanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-tetradecyloctadecanoic acid(73756-39-5)
• EPA Substance Registry System: 2-tetradecyloctadecanoic acid(73756-39-5)

Safety Data

• Hazardous Substances Data: 73756-39-5(Hazardous Substances Data)

Usage

General Description

2-tetradecyloctadecanoic acid, also known as 2-TDO or 2-TA, is a fatty acid with a unique chemical structure. It is a long-chain saturated fatty acid with 28 carbon atoms and a carboxylic acid group. 2-TDO is known for its potential anti-inflammatory and antidiabetic properties, as well as its ability to modulate lipid metabolism. It has been studied for its role in various biological processes, including energy metabolism, insulin sensitivity, and inflammation. 2-TDO has also been investigated for its potential therapeutic applications in the treatment of obesity, diabetes, and cardiovascular diseases. Overall, 2-tetradecyloctadecanoic acid shows promise as a bioactive compound with potential health benefits.

InChI:InChI=1/C32H64O2/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-31(32(33)34)29-27-25-23-21-19-16-14-12-10-8-6-4-2/h31H,3-30H2,1-2H3,(H,33,34)

Upstream product

• 32582-32-4 2-tetradecyl-octadecanol 
• 19218-94-1 1-iodotetradecane 
• 57-11-4 stearic acid 
• 54580-47-1 diethyl 2-tetradecylmalonate 
• 112-82-3 hexadecanyl bromide 
• 36653-82-4 1-Hexadecanol 

Downstream Products

• 1416474-30-0 C₁₁₈H₁₈₂O₁₃ 

Relevant articles and documents

Tris(2-aminoethyl)amine-based α-branched fatty acid amides - Synthesis of lipids and comparative study of transfection efficiency of their lipid formulations This article is dedicated to Professor Gerald Brezesinski on occasion of his 65th birthday.

The synthesis of a new class of cationic lipids, tris(2-aminoethyl)amine-based α-branched fatty acid amides, is described resulting in a series of lipids with specific variations in the lipophilic as well as the hydrophilic part of the lipids. In-vitro structure/transfection relationships were established by application of complexes of these lipids with plasmid DNA (pDNA) to different cell lines. The α-branched fatty acid amide bearing two tetradecyl chains and two lysine molecules (T14diLys) in mixture with the co-lipid 1,2-di-[(9Z)-octadec-9-enoyl]-sn-glycero-3-phosphoethanolamine (DOPE) (1/2, n/n) exhibits effective pDNA transfer in three different cell lines, namely Hep-G2, A549, and COS-7. The presence of 10% serum during lipoplex incubation of the cells did not affect the transfection efficiency. Based on that, detailed investigations of the complexation of pDNA with the lipid formulation T14diLys/DOPE 1/2 (n/n) were carried out with respect to particle size and charge using dynamic light scattering (DLS), ζ-potential measurements, and transmission electron microscopy (TEM). Additionally, the lipoplex uptake was investigated by confocal laser scanning microscopy (CLSM). Overall, lipoplexes prepared from T14diLys/DOPE 1/2 (n/n) offer large potential as lipid-based polynucleotide carriers and further justify advanced examinations.

Development of vizantin, a safe immunostimulant, based on the structure-activity relationship of trehalose-6,6′-dicorynomycolate

Vizantin, 6,6′-bis-O-(3-nonyldodecanoyl)-α,α′- trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6′- dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.